Investing.com -- Entera Bio Ltd. (NASDAQ:ENTX) stock rose 3.5% in Thursday’s premarket trading following the company’s presentation of new clinical data from its Phase 2 trial of EB613, an oral ...
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613’s efficacy in both young postmenopausal women and in women 10 years ...
TipRanks on MSN
Entera Bio presents clinical data from EB613 Phase 2 trial
Entera Bio (ENTX) reported new clinical data from a post-hoc analysis of its Phase 2 trial of EB613, at the 2025 North American Menopause Society ...
Asian News International on MSN
Tripura Civil Society calls ‘24-Hour Bandh’ over Tiprasa Accord, Infiltration Issues in Agartala
Tripura Civil Society called for ‘24-hour Tripura bandh’. They demanded action against illegal immigration, implementation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback